A Look At Oscar Health (OSCR) Valuation As Earnings Projections And Margins Improve

Attention around Oscar Health (OSCR) is building ahead of its forthcoming earnings release, where projections point to a significantly higher EPS than a year ago, set alongside expanding margins and rising operational efficiency.
See our latest analysis for Oscar Health.
Despite the upcoming earnings focus, recent trading has been weak, with a 30 day share price return showing a decline of 13.98% and a year to date share price return showing a decline of 25.58%, while the 3 year total shareholder return of 70.34% suggests the longer term picture has been much stronger.
If this kind of earnings driven story interests you, it can be worth widening your search with a curated list of 34 healthcare AI stocks
With Oscar Health shares down sharply in recent months despite higher EPS projections and improving margins, the key question is whether current weakness leaves the stock undervalued or whether the market is already pricing in future growth potential.
Most Popular Narrative: 29.4% Undervalued
Oscar Health’s most followed valuation narrative pegs fair value at about $15.78 per share, well above the last close of $11.14. This puts a spotlight on what assumptions need to hold for that gap to close.
The analysts have a consensus price target of $11.143 for Oscar Health based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.
Want to see why this narrative still points to upside even as targets and trading diverge? Earnings turning positive, margins shifting, and a richer future multiple all sit at the core of the model, along with a specific view on revenue growth and share count that could change how you see that $15.78 figure.
Result: Fair Value of $15.78 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are still clear risks, including higher claims costs from changing ACA risk pools and policy shifts that could pressure membership growth and future margins.
Find out about the key risks to this Oscar Health narrative.
Next Steps
With sentiment clearly mixed, both on recent price moves and future earnings, it makes sense to review the data yourself and decide where you stand. To see how the balance of concerns and potential upside currently looks, check out the 2 key rewards and 1 important warning sign
Looking for more investment ideas?
If you stop with Oscar Health, you could miss other opportunities that fit your style, so take a few minutes to scan the wider market with focused stock lists.
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com




